{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:33:59Z","timestamp":1792953239275,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13555-026-01922-8","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:35:35Z","timestamp":1790926535000},"page":"5653-5667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tralokinumab Versus Dupilumab for the Treatment of Atopic Dermatitis with Moderate-to-Severe Hand Involvement: A Matching-Adjusted Indirect Comparison"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0831-2151","authenticated-orcid":false,"given":"Leon","family":"Kircik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5482-680X","authenticated-orcid":false,"given":"Andrei","family":"Metelitsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5706-813X","authenticated-orcid":false,"given":"Adrian","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3543-4848","authenticated-orcid":false,"given":"Sebastian","family":"Volc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5885-3909","authenticated-orcid":false,"given":"Naiem","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-399X","authenticated-orcid":false,"given":"Raj","family":"Chovatiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2355-8667","authenticated-orcid":false,"given":"Rie","family":"von Eyben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Festini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6287-7508","authenticated-orcid":false,"given":"Pierre","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6380-5226","authenticated-orcid":false,"given":"Benjamin","family":"Ehst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"1922_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396:345\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)31286-1.","journal-title":"Lancet"},{"key":"1922_CR2","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","volume":"34","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Christen-Zach S, Taieb A, et al. ETFAD\/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34:2717\u201344. https:\/\/doi.org\/10.1111\/jdv.16892.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1922_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2310\/6620.2006.06005","volume":"17","author":"EL Simpson","year":"2006","unstructured":"Simpson EL, Thompson MM, Hanifin JM. Prevalence and morphology of hand eczema in patients with atopic dermatitis. Dermatitis. 2006;17:123\u20137. https:\/\/doi.org\/10.2310\/6620.2006.06005.","journal-title":"Dermatitis"},{"key":"1922_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-025-04138-6","volume":"317","author":"JI Silverberg","year":"2025","unstructured":"Silverberg JI, Samynathan A, Thyssen JP. Prevalence, severity and predictors of hand eczema in patients treated for atopic dermatitis: a cross-sectional observational study. Arch Dermatol Res. 2025;317:652. https:\/\/doi.org\/10.1007\/s00403-025-04138-6.","journal-title":"Arch Dermatol Res"},{"key":"1922_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jaad.2023.04.052","volume":"89","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Simpson B, Abuabara K, et al. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: a cross-sectional study from the TARGET-DERM AD cohort. J Am Acad Dermatol. 2023;89:519\u201328. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.052.","journal-title":"J Am Acad Dermatol"},{"key":"1922_CR6","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","volume":"139","author":"LC Tsoi","year":"2019","unstructured":"Tsoi LC, Rodriguez E, Degenhardt F, et al. Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019;139:1480\u20139. https:\/\/doi.org\/10.1016\/j.jid.2018.12.018.","journal-title":"J Invest Dermatol"},{"key":"1922_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","volume":"75","author":"T Bieber","year":"2020","unstructured":"Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75:54\u201362. https:\/\/doi.org\/10.1111\/all.13954.","journal-title":"Allergy"},{"key":"1922_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40257-024-00913-9","volume":"26","author":"J Gorelick","year":"2025","unstructured":"Gorelick J, Nguyen A, Schneider SKR, Martel BC, Madsen DE, Armstrong AW. Biomarkers in atopic dermatitis: a review of the role of IL-13 and the impact of tralokinumab treatment. Am J Clin Dermatol. 2025;26:199\u2013211. https:\/\/doi.org\/10.1007\/s40257-024-00913-9.","journal-title":"Am J Clin Dermatol"},{"key":"1922_CR9","doi-asserted-by":"publisher","first-page":"745.e1","DOI":"10.1016\/j.jaad.2025.05.1386","volume":"93","author":"DMR Davis","year":"2025","unstructured":"Davis DMR, Frazer-Green L, Alikhan A, et al. Focused update: guidelines of care for the management of atopic dermatitis in adults. J Am Acad Dermatol. 2025;93:745.e1-745.e7. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1386.","journal-title":"J Am Acad Dermatol"},{"key":"1922_CR10","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1111\/jdv.20639","volume":"39","author":"A Wollenberg","year":"2025","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: living update. J Eur Acad Dermatol Venereol. 2025;39:1537\u201366. https:\/\/doi.org\/10.1111\/jdv.20639.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1922_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","volume":"429","author":"B Popovic","year":"2017","unstructured":"Popovic B, Breed J, Rees DG, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13R\u03b11 and IL-13R\u03b12. J Mol Biol. 2017;429:208\u201319. https:\/\/doi.org\/10.1016\/j.jmb.2016.12.005.","journal-title":"J Mol Biol"},{"key":"1922_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100214","volume":"3","author":"MAX Tollenaere","year":"2023","unstructured":"Tollenaere MAX, M\u00f8lck C, Henderson I, et al. Tralokinumab effectively disrupts the IL-13\/IL-13R\u03b11\/IL-4R\u03b1 signaling complex but not the IL-13\/IL-13R\u03b12 complex. JID Innov. 2023;3:100214. https:\/\/doi.org\/10.1016\/j.xjidi.2023.100214.","journal-title":"JID Innov"},{"key":"1922_CR13","doi-asserted-by":"publisher","first-page":"s744","DOI":"10.25251\/ppt8ep84","volume":"10","author":"B Ehst","year":"2026","unstructured":"Ehst B, Warren RB, Chih-ho Hong H, et al. Tralokinumab treatment in patients with atopic dermatitis and moderate-to-severe hand involvement: results from the 32-week phase\u00a03b ADHAND trial. J Skin. 2026;10:s744. https:\/\/doi.org\/10.25251\/ppt8ep84.","journal-title":"J Skin"},{"key":"1922_CR14","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.jaad.2023.12.066","volume":"90","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Silverberg JI, Worm M, et al. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: results from a phase\u00a03, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024;90:1190\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"1922_CR15","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15:940\u20137.","journal-title":"Value Health"},{"key":"1922_CR16","doi-asserted-by":"publisher","first-page":"2169574","DOI":"10.1080\/09546634.2023.2169574","volume":"34","author":"J Signorovitch","year":"2023","unstructured":"Signorovitch J, Diels J, Van Sanden S, et al. Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis. J Dermatolog Treat. 2023;34:2169574.","journal-title":"J Dermatolog Treat"},{"key":"1922_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38:200\u201311.","journal-title":"Med Decis Making"},{"key":"1922_CR18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s13555-024-01114-2","volume":"14","author":"S Molin","year":"2024","unstructured":"Molin S, Larsen LS, Joensson P, et al. Development and psychometric validation of a patient-reported outcome measure to assess the signs and symptoms of chronic hand eczema: the Hand Eczema Symptom Diary (HESD). Dermatol Ther (Heidelb). 2024;14:643\u201369. https:\/\/doi.org\/10.1007\/s13555-024-01114-2.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1922_CR19","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jaad.2019.06.018","volume":"81","author":"A Egeberg","year":"2019","unstructured":"Egeberg A, Thyssen JP. Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis. J Am Acad Dermatol. 2019;81:943\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.018.","journal-title":"J Am Acad Dermatol"},{"key":"1922_CR20","doi-asserted-by":"publisher","first-page":"171035682514097","DOI":"10.1177\/17103568251409795","volume":"6","author":"G Patel","year":"2026","unstructured":"Patel G, Thyssen JP, Silverberg JI. Hand eczema is independently associated with significant quality of life impact in patients with atopic dermatitis. Dermatitis. 2026;6:17103568251409796. https:\/\/doi.org\/10.1177\/17103568251409795.","journal-title":"Dermatitis"},{"key":"1922_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46540-0","volume":"15","author":"C Bangert","year":"2024","unstructured":"Bangert C, Alkon N, Chennareddy S, et al. Dupilumab-associated head and neck dermatitis shows a pronounced type\u00a022 immune signature mediated by oligoclonally expanded T\u00a0cells. Nat Commun. 2024;15:2839. https:\/\/doi.org\/10.1038\/s41467-024-46540-0.","journal-title":"Nat Commun"},{"key":"1922_CR22","doi-asserted-by":"publisher","first-page":"565","DOI":"10.14744\/cpr.2025.61241","volume":"47","author":"B Xu","year":"2025","unstructured":"Xu B, Zhang X, Zhang C, Zeng W, Zeng K, Li C. Dupilumab-induced immune drift phenomena in atopic dermatitis: novel insights into mechanisms and therapeutic strategies. J Clin Pract Res. 2025;47:565\u201372. https:\/\/doi.org\/10.14744\/cpr.2025.61241.","journal-title":"J Clin Pract Res"},{"issue":"1","key":"1922_CR23","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2022.12.e1","volume":"12","author":"YJ Kim","year":"2022","unstructured":"Kim YJ, Lee MY, Won CH. Acral erythema arising in patients with atopic dermatitis after dupilumab therapy: a case report of 3 patients. Asia Pac Allergy. 2022;12(1):e1. https:\/\/doi.org\/10.5415\/apallergy.2022.12.e1.","journal-title":"Asia Pac Allergy"},{"key":"1922_CR24","doi-asserted-by":"publisher","first-page":"16078","DOI":"10.3389\/jcia.2026.16078","volume":"9","author":"K Kono","year":"2026","unstructured":"Kono K, Sakai T, Hatano Y. Exacerbation of hand rash after dupilumab initiation in a child with atopic dermatitis who was able to continue treatment. J Cutan Immunol Allergy. 2026;9:16078.","journal-title":"J Cutan Immunol Allergy"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01922-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01922-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01922-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:00:53Z","timestamp":1792951253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01922-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1922"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01922-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"April Armstrong: has served as a research investigator and\/or scientific advisor to AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, LEO Pharma, UCB, Janssen, Lilly, Nimbus, Novartis, OrthoDermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and Modmed. Leon Kircik: served as an investigator (received grant) for AbbVie, Acambis, Amgen, Inc., Anacor Pharmaceuticals, Anaptys, Arcutis, Arena, Astellas Pharma US, Inc., Asubio, Biomimetrix, Biosion, Dermavant, Dermira, Dow Pharmaceutical Sciences, Inc., Eli Lilly and Company, Ferndale Laboratories, Inc., Galderma, Genentech, Inc., GlaxoSmithKline, plc, Glenmark, Health Point, Ltd, Incyte, LEO Pharma, L\u2019Or\u00e9al, Nano Bio, Nektar, Novartis AG, Nucryst Pharmaceuticals Corp, Onset, OrthoDermatologics, OrthoNeutrogena, Promius, PharmaDerm, Pfizer, Quinnova, Rapt, Regeneron, Sanofi, SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Valeant Pharmaceuticals Intl. Consultant (received honorarium) for AbbVie, Amgen, Inc., Anacor Pharmaceuticals, Arcutis, Biosion, Dermavant, Dermira (received grant), Eli Lilly and Company, Galderma, Genentech, Inc., LEO Pharma, Nektar, Novartis AG, OrthoDermatologics, OrthoNeutrogena, Promius, PuraCap, Rapt, Sanofi, SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Valeant Pharmaceuticals Intl. Speaker (received honorarium) for Amgen, Inc., Assos Pharma, Astellas Pharma US, Inc., Dermira (received grant), Eli Lilly and Company, Galderma, Genentech, Inc., Innocutis, Innovail, Kyowakirin, LEO Pharma, L\u2019Or\u00e9al, Novartis AG, Onset, OrthoDermatologics, OrthoNeutrogena, PediaPharma, PharmaDerm, Regeneron, Sanofi, SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Triax, Valeant Pharmaceuticals Intl. Advisory board member (received honorarium) for Anacor Pharmaceuticals, Arcutis, Arena, Dermavant, Dermira (received grant), Eli Lilly and Company, Ferndale Laboratories, Inc., Galderma, Genentech, Inc., Glenmark, Incyte, Innocutis, Nano Bio, Novartis AG, OrthoDermatologics, OrthoNeutrogena, Promius, Quinnova, Sanofi, SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Valeant Pharmaceuticals Intl. Consultant\/speaker for Taro (received honorarium). Andrei Metelitsa: has served as a research investigator, speaker and\/or scientific advisor to AbbVie, Amgen, Arcutis, Apogee, Bausch Health, BMS, Eli Lilly, Galderma, Janssen, Incyte, LEO Pharma, Novartis, Organon, Oruka, Pfizer, Sanofi, Sun Pharma, Takeda, UCB. Richard B Warren: has received research grants from AbbVie, Almirall, Amgen, Celgene, Janssen, Lilly, LEO Pharma, Novartis, Pfizer and UCB; and consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DiCE, Galderma, GSK, Immunocore, Indero, Janssen, Lilly, LEO Pharma, Meiji Pharma, Nektar Therapeutics, Novartis, Pfizer, RAPT pharmaceuticals, Sanofi, Sun Pharma, Takeda, UCB and UNION. Richard B Warren is an Editor-in-Chief of\n                      Dermatology and Therapy\n                      . Richard B Warren was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Adrian Rodriguez: has reported personal fees from Johnson & Johnson, Sun Pharma, UCB, AbbVie, LEO Pharma, Incyte, Pfizer, Eli Lilly, and Arcutis. Sebastian Volc: has served as a research investigator and\/or scientific advisor to AbbVie, Almirall, Amgen, Apogee Therapeutics, Blueprint, Celldex, Galapagos, Galderma, HyPharm, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Sanofi, Regeneron, Pfizer, Takeda, and UCB. Naiem Issa: received funding from the following entities either as a speaker, consultant, advisor, or investigator: AbbVie, Almirall, Apogee, Bristol Myers Squibb, Castle Biosciences, Dermavant Sciences, DermTech, Galderma, Incyte, Janssen, Journey, LEO Pharma, Lilly, OrthoDermatologics, Pfizer, Primus, Regeneron, Sanofi, SUN Pharmaceuticals Industry, Topix, UCB, and Verrica Pharmaceuticals. Raj Chovatiya: has served as an advisor, consultant, speaker, and\/or investigator for AbbVie, Acelyrin, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics, Argenx, Astria Therapeutics, Avalere Health, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celldex Therapeutics, CLn Skin Care, Dermavant, Eli Lilly and Company, EMD Serono, Formation Bio, Forte Biosciences, Galderma, Genentech, GSK, Incyte, Imagene Bio Inc., Johnson & Johnson, Kenvue, Kowa Pharmaceuticals America, LEO Pharma, L\u2019Or\u00e9al, Nektar Therapeutics, Nia Health, Novartis, Opsidio, Organon, Pfizer, RAPT, Regeneron, Sanofi, Sitryx, SUN Pharma, Takeda, TRex Bio, UCB, and Zai Lab. Rie von Eyben and Teodora Festini are employees of LEO Pharma A\/S. Pierre Johansen was an employee of LEO Pharma A\/S at the time of the analysis and manuscript development. Benjamin Ehst: has served as a speaker, consultant, and\/or receives honoraria\/grants from AbbVie, Acelyrin, Aclaris, Allakos, Almirall, Alumis, Amgen, AnaptysBio, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert Pharma, Dermavant Sciences, Inc., Eli Lilly, Evelo Biosciences, Evommune, Incyte, Janssen, Kymab, LEO Pharma, Novartis, OrthoDermatologics, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Takeda, UCB Pharma, and Ventyx.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}